New Delhi: The Delhi High Court on Tuesday called for responses from the government, the Central Drugs Standard Control Organisation (CDSCO), and other concerned authorities regarding a contempt petition that alleges a failure to act on earlier court directions to examine reports of misuse of diabetes drugs, including Ozempic, for weight loss purposes.The matter came up before Justice Sachin Datta, who issued notices to the concerned parties and directed them to submit their replies.As per the recent media report by The Economic Times, the court specifically asked authorities to clarify whether any steps had been taken in compliance with its earlier directions regarding the alleged off-label use of such medications.Also Read: GLP-1 drugs like Ozempic could cut risk of major heart complications after heart attack, study findsThe court also issued notice to the Drugs Controller General of India (DCGI) and granted four weeks to respond to the contempt petition filed by Jitendra Chouksey, CEO of Pune-based healthtech startup Fittr. The petitioner has urged the court to initiate contempt proceedings against CDSCO for not adhering to prior directions to assess concerns over the off-label use of drugs like Ozempic for weight loss.The Economic Times reports that the court has now scheduled the matter for its next hearing on May 21.Also Read: India’s Semaglutide Market Set for Generic Boom as Patents Expire, Over 50 Brands Lined Up for Launch, See Full List